Policy & Regulation
Tubulis and Glycotope Ink Research and Feasibility Agreement for the Discovery of Antibody Drug Conjugates
13 September 2019 - - German protein drug conjugates developer Tubulis and Glycotope, a clinical-stage immuno-oncology company, have signed a research and feasibility agreement, providing Glycotope ac...
Gamida Cell and the CIBMTR Collaborate to Advance Research for Cellular Therapy
...
Castle Creek Pharmaceutical Holdings to acquire Fibrocell Science
13 September 2019 - It was reported yesterday that Castle Creek Pharmaceutical Holdings, Inc, a privately held holding company that holds and invests in companies in the orphan dermatology space, has ...
Roche's Tecentriq improves overall survival rate in IMpower110 study
13 September 2019 - Switzerland-based Roche's lung cancer drug Tecentriq (atezolizumab) has improved overall survival rate in a phase III IMpower110 study, it was reported yesterday.The trial is ...
VBI Vaccines collaborates with GlaxoSmithKline to asses drug combination
13 September 2019 - United States-based VBI Vaccines has collaborated with United Kingdom-based GlaxoSmithKline to clinically assess the combination of VBI-1901, VBI's cancer vaccine immunotherap...
Biosortia names new director
12 September 2019 - It was reported yesterday that Biosortia, a drug discovery company focused on natural microbiomes, has named Dr John Ryals as its new Director.The new Director is the founder of Me...
Related Headlines

Merck commences two global Phase III trials of Evobrutinib

New Data from Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients with Major Depressive Disorder Who Have Active Suicidal Ideation with Intent

MicuRx Pharmaceuticals Touts Positive Top-Line Results from a US Phase 2 ABSSSI Clinical Trial of Novel Antibiotic Contezolid Acefosamil

Fractyl Touts Positive Topline Results in the Revita-2 Clinical Trial in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Bellus Health Raises USD 70m from Stock Offering

Alexion, BridgeBio Ink Japanese License Agreement for Eidos' Transthyretin Amyloidosis Investigational Medicine

New Preclinical Research Suggests Tetra Therapeutics' BPN14770 Protects Against Memory Loss and Neuronal Atrophy in Alzheimer's Disease

Personalis Enters Into Research Agreement with Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial

US FDA has Granted Priority Review of the Teprotumumab Biologics License Application for the Treatment of Active Thyroid Eye Disease

Ayala Pharmaceuticals names Gordon as Chief Medical Officer

Yuva Biosciences names new Advisory Board members

Imfinzi improves overall patient survival in AstraZeneca's phase III Caspian study

US FDA grants Orphan Drug designation to Acceleron Pharma's Sotatercept

Pfizer Touts Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

Oncternal Appoints Kaufmann as Chief Scientific Officer, Bilinsky as Chief Business Officer